CISPLASAN is indicated as palliative therapy either alone or in combination with other approved chemotherapeutic against and in patients who have already received appropriate surgical and/or radio therapeutic procedures in the management of metastatic testicular tumors or metastatic ovarian tumors and advanced bladder cancer.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
